Skip to content

Study on the efficacy and mechanism ofXie-Tu-He-Mu-Gao in improving MASLD of ' spleen deficiency and phlegm dampness syndrome ' by regulating gastrointestinal function

Study on the efficacy and mechanism of xie tu he mu gao in improving MASLD of ' spleen deficiency and phlegm dampness syndrome ' by regulating gastrointestinal function

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000877
Enrollment
Unknown
Registered
2024-12-27
Start date
2024-10-17
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic dysfunction-associated steatotic liver disease

Interventions

control group:Lifestyle intervention therapy
Treatment group:Xie-Tu-He-Mu-Gao combined with lifestyle intervention therapy

Sponsors

Nanjing University of Traditional Chinese Medicine Affiliated Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients between the ages of 18 and 75 regardless of gender; (2) Meets the diagnostic criteria of MASLD and has good patient compliance; (3) The TCM syndrome type conforms to the "spleen deficiency phlegm dampness syndrome"; (4) Regular eating habits stable weight in the past three months and no excessive drinking or binge eating in the past two weeks; (5) Not taking or discontinuing relevant gastric motility promoting drugs for more than two days; (6) I have not participated in any other clinical observation projects in the past three months; (7) Voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Medications related to secondary MASLD (corticosteroids estrogen amiodarone methotrexate) are currently being used. (2) Complicated with serious primary system diseases such as respiratory circulatory digestive urinary nervous blood rheumatism endocrine system diseases tumors AIDS etc. (3) Patients with liver dysfunction caused by the combination of alcoholic fatty liver disease viral hepatitis autoimmune liver disease liver tumors etc. (4) Pregnant or lactating women. (5) Individuals with allergies or known potential allergies or intolerance to the drugs used in this study. (6) Individuals with severe cognitive impairment or mental illness.

Design outcomes

Primary

MeasureTime frame
NFS score FIB-4 index;Gastrointestinal Electrogram;Fibroscan;

Secondary

MeasureTime frame
Glucose and lipid metabolism indicators;Traditional Chinese Medicine Syndrome Score;Liver function and inflammatory indicators;

Countries

China

Contacts

Public ContactLou Yan

Nanjing University of Traditional Chinese Medicine Affiliated Jiangsu Provincial Hospital of Traditional Chinese Medicine

louyan910118@163.com15996253391

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026